Terminated PHASE1 INTERVENTIONAL 1-arm NCT00887926

Study of IMC-EB10 in Participant With Leukemia

An Open-label, Dose Escalation, Phase I Study of IMC-EB10 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Sponsor: Eli Lilly and Company

Conditions Myeloid Leukemia

Interventions IMC-EB10

Updated 10 times since 2017 Last updated: Dec 20, 2022 Started: Jun 30, 2009 Primary completion: Aug 31, 2010 Completion: Aug 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Lack of efficacy

Other terminated trials from Eli Lilly and Company

See all terminations from Eli Lilly and Company

A PHASE1 clinical study on Myeloid Leukemia, this trial is terminated or withdrawn. The trial is conducted by Eli Lilly and Company and has accumulated 10 data snapshots since 2009. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Jan 2023 — Jul 2024 [monthly]

Terminated PHASE1
Dec 2021 — Jan 2023 [monthly]

Terminated PHASE1
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE1

▶ Show 5 earlier versions

Nov 2019 — Jan 2021 [monthly]

Terminated PHASE1
Oct 2019 — Nov 2019 [monthly]

Terminated PHASE1
Jun 2018 — Oct 2019 [monthly]

Terminated PHASE1
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE1
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE1

First recorded

Jun 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company

Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Columbus, United States
• Houston, United States